Latest news with #treatmentoptions
Forbes
6 days ago
- Health
- Forbes
Dr. Ryan Beck: Dry Eye Isn't Going Away Anytime Soon
Dry Eye Disease affects millions of Americans, yet many patients still think the only solution is to grab a bottle of artificial tears from the pharmacy shelf. According to Dr. Ryan Beck, a leading optometrist recently featured on The Dry Eye Podcast by Broadry, the reality is that treatment options have evolved far beyond basic drops—ushering in an era of high-tech, in-office procedures that are transforming patient outcomes. 'We start with simple management tools—over-the-counter drops, nutraceuticals, lid cleansers, and wipes,' Beck says. 'But today, there's an entire spectrum of therapies available that address the root causes of dry eye.' From Restasis to a Full Pharmaceutical Arsenal When Restasis launched in the early 2000s, it was the only FDA-approved prescription option for chronic dry eye. Fast-forward to today, and patients have access to a range of medications that reduce inflammation, improve tear production, and protect the ocular surface. Newer prescription drops are more targeted, faster-acting, and in some cases, better tolerated—giving practitioners more flexibility to tailor treatments. In-Office Devices: Borrowing From Aesthetics Beyond pharmaceuticals, Beck highlights a trend that's crossing over from the beauty and dermatology world. Intense Pulse Light (IPL) therapy (invented by Dr. Rolando Toyos) originally designed for skin rejuvenation, has become a powerful tool in treating meibomian gland dysfunction, a leading cause of dry eye. By reducing inflammation and improving oil flow in the eyelids, IPL addresses tear film stability at its source. Another innovation: radiofrequency (RF) devices that stimulate collagen production and tighten skin around the eyes. 'A better eyelid seal means a better blink,' Beck explains, 'and that's critical for tear retention.' Photobiomodulation The red-light therapy devices that have exploded in the hair restoration market are also making waves in dry eye treatment. Photobiomodulation appears to boost oil gland function, potentially reducing evaporative dry eye symptoms. Early research is promising, and many clinics are already integrating specific light technology into their treatment menus. Why This Matters Now With dry eye prevalence increasing, due in part to screen-heavy lifestyles, environmental factors, and aging populations, the demand for more effective, lasting treatments is only growing. 'Dry eye isn't going away anytime soon,' says Beck. 'The better we can manage it, the happier our patients will be.' In other words, the future of dry eye care lies in personalization, prevention, and a willingness to embrace technology from unexpected places. And for patients, that means relief is no longer limited to what's on the drugstore shelf.
Associated Press
22-06-2025
- Health
- Associated Press
Key Findings from the "Hong Kong Vitiligo Patients and Caregivers Survey" Released for "World Vitiligo Day"
Patients Demonstrate Significant Knowledge Gaps in Treatment Options, Leading to Lost Hope and Treatment Discontinuation Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results HONG KONG SAR - Media OutReach Newswire - 22 June 2025 - In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest 'Hong Kong Vitiligo Patients and Caregivers Survey.' The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation. (From left) Mr. Chan (pseudonym), a patient with vitiligo; Dr. Chan Yung, a specialist in dermatology; and Ms. Amy Wong, a registered social worker from the Hong Kong Vitiligo Support Group, urge individuals with vitiligo to seek professional medical consultation for personalized treatment plan promptly and to avoid unproven remedies Dr. Chan Yung, a specialist in dermatology, noted that with advancing insights into vitiligo pathogenesis, novel therapy has recently been introduced in Hong Kong. Clinical studies confirm its repigmentation potential, encouraging patients to consult specialists for personalized treatment plans. In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows: 1. Critical Knowledge Deficits in Treatment Understanding 2. Disparity Between Treatment Expectations and Outcomes 3. Treatment Discontinuation Due to Lost Confidence Vitiligo is classified as segmental (SV) or non-segmental (NSV), with 90% of cases being NSV—a subtype with higher progression risk and greater therapeutic difficulty. Traditional options (e.g., topical corticosteroids, topical calcineurin inhibitors, phototherapy) often yield variable results, with limitations such as: Over 70% of Vitiligo Patients Seek Skin Repigmentation - New Topical Treatment Introduced in Hong Kong Offers Hope Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. 'Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients,' he explained. While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas. Ruxolitinib cream, the first FDA-approved non-steroidal topical JAK inhibitor for localized treatment of non-segmental vitiligo in patients aged 12 years and above, has recently become available in Hong Kong. Clinical trials show: Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. 'Many patients spend over a year just obtaining a definitive diagnosis,' she explained. 'In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress.' 'However,' Ms. Wong emphasized, 'with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity.' Conclusion and Recommendations The survey reveals significant gaps in patients' understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations: 1. Public Education Seminars Conduct lectures and workshops to help patients and caregivers understand that vitiligo requires long-term management, with visible results often taking extended periods to manifest. These initiatives should also educate participants about various treatment modalities, particularly newly available options like non-steroidal topical JAK inhibitors, enabling informed discussions with healthcare providers about appropriate treatment plans. 2. Medication Support and Resource Referral Services Given that vitiligo necessitates prolonged treatment, and considering that many patients find private care cost-prohibitive while public service wait times are excessively long, we recommend establishing medication support and resource referral services to facilitate timely access to proper treatment. Hong Kong Vitiligo Support Group is currently implementing a 'Vitiligo Patient Support Program,' offering free psychological counseling, medication assistance, and resource referral services. Interested individuals may contact Hong Kong Vitiligo Support Group for details. Case Study Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially 'incurable.' Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages - exhausting savings and liquidating his stocks - all without achieving satisfactory repigmentation. After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and 'Vitiligo Patient Support Program', he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation. 'My greatest wish is to wear crew-neck shirts again,' Mr. Chan shared. 'Since developing vitiligo, I've only worn high-collared shirts to conceal neck patches and haven't gone swimming in thirty years.' He looks forward to regaining sartorial freedom following successful repigmentation. Hashtag: #Vitiligo #WorldVitiligoDay #TopicalJAKinhibitors #Non-steroidalTopicalJAKinhibitors #Ruxolitinibcream #SkinRepigmentation # #Dermatology #Skincare#HongKongVitiligoSupportGroup The issuer is solely responsible for the content of this announcement. About Hong Kong Vitiligo Support Group Initiated by social enterprise Hong Kong Health Care Alliance, Hong Kong Vitiligo Support Group is a non-profit patient organization dedicated to individuals affected by vitiligo and their caregivers. Our mission is to enhance societal understanding of vitiligo through comprehensive disease education and support services, empowering patients to better understand and confront their condition while fostering public awareness. We strive to ensure no patient faces this journey alone.
Zawya
22-06-2025
- Health
- Zawya
Key Findings from the "Hong Kong Vitiligo Patients and Caregivers Survey" Released for "World Vitiligo Day"
Patients Demonstrate Significant Knowledge Gaps in Treatment Options, Leading to Lost Hope and Treatment Discontinuation Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results HONG KONG SAR - Media OutReach Newswire - 22 June 2025 - In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest "Hong Kong Vitiligo Patients and Caregivers Survey." The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation. Dr. Chan Yung, a specialist in dermatology, noted that with advancing insights into vitiligo pathogenesis, novel therapy has recently been introduced in Hong Kong. Clinical studies confirm its repigmentation potential, encouraging patients to consult specialists for personalized treatment plans. In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows: 1. Critical Knowledge Deficits in Treatment Understanding 80% lack understanding of treatment options 78% unfamiliar with medication efficacy 84% uncertain about which specialist to consult 2. Disparity Between Treatment Expectations and Outcomes 74% of respondents expressed a desire for full or partial skin repigmentation, yet among the 48 treated patients, none achieved complete repigmentation, and only 8% reported partial improvement 67% perceived treatments as completely ineffective 3. Treatment Discontinuation Due to Lost Confidence 43% are not receiving any active treatment at present Barriers included: high private healthcare costs and long public-sector wait times (95%), and perceived futility of therapy (75%) Vitiligo is classified as segmental (SV) or non-segmental (NSV), with 90% of cases being NSV—a subtype with higher progression risk and greater therapeutic difficulty. Traditional options (e.g., topical corticosteroids, topical calcineurin inhibitors, phototherapy) often yield variable results, with limitations such as: Corticosteroids: Risk of skin atrophy, telangiectasia; unsuitable for long-term use Phototherapy: Requires 3–6 months (or longer) of 2–3 weekly sessions, with potential sunburn and skin cancer risks Non-steroidal topicals: Often only slow progression rather than induce repigmentation Over 70% of Vitiligo Patients Seek Skin Repigmentation - New Topical Treatment Introduced in Hong Kong Offers Hope Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. "Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients," he explained. While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas. Ruxolitinib cream, the first FDA-approved non-steroidal topical JAK inhibitor for localized treatment of non-segmental vitiligo in patients aged 12 years and above, has recently become available in Hong Kong. Clinical trials show: Approximately 30% of patients achieved ≥75% improvement in Facial Vitiligo Area Scoring Index (F-VASI) after 24 weeks of treatment; 50% of patients showed ≥50% improvement; Extension to 52 weeks of treatment resulted in >50% of patients attaining ≥75% improvement 7 Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. "Many patients spend over a year just obtaining a definitive diagnosis," she explained. "In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress." "However," Ms. Wong emphasized, "with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity." Conclusion and Recommendations The survey reveals significant gaps in patients' understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations: 1. Public Education Seminars Conduct lectures and workshops to help patients and caregivers understand that vitiligo requires long-term management, with visible results often taking extended periods to manifest. These initiatives should also educate participants about various treatment modalities, particularly newly available options like non-steroidal topical JAK inhibitors, enabling informed discussions with healthcare providers about appropriate treatment plans. 2. Medication Support and Resource Referral Services Given that vitiligo necessitates prolonged treatment, and considering that many patients find private care cost-prohibitive while public service wait times are excessively long, we recommend establishing medication support and resource referral services to facilitate timely access to proper treatment. Hong Kong Vitiligo Support Group is currently implementing a "Vitiligo Patient Support Program," offering free psychological counseling, medication assistance, and resource referral services. Interested individuals may contact Hong Kong Vitiligo Support Group for details. Case Study Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially "incurable." Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages - exhausting savings and liquidating his stocks - all without achieving satisfactory repigmentation. After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and "Vitiligo Patient Support Program", he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation. "My greatest wish is to wear crew-neck shirts again," Mr. Chan shared. "Since developing vitiligo, I've only worn high-collared shirts to conceal neck patches and haven't gone swimming in thirty years." He looks forward to regaining sartorial freedom following successful repigmentation. Hashtag: #Vitiligo #WorldVitiligoDay #TopicalJAKinhibitors #Non-steroidalTopicalJAKinhibitors #Ruxolitinibcream #SkinRepigmentation # #Dermatology #Skincare#HongKongVitiligoSupportGroup The issuer is solely responsible for the content of this announcement. About Hong Kong Vitiligo Support Group Initiated by social enterprise Hong Kong Health Care Alliance, Hong Kong Vitiligo Support Group is a non-profit patient organization dedicated to individuals affected by vitiligo and their caregivers. Our mission is to enhance societal understanding of vitiligo through comprehensive disease education and support services, empowering patients to better understand and confront their condition while fostering public awareness. We strive to ensure no patient faces this journey alone. Hong Kong Vitiligo Support Group
Globe and Mail
12-06-2025
- Business
- Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6 th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram.
National Post
12-06-2025
- Health
- National Post
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6 th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Article content Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content Article content Gabriel Fahel Article content Article content Article content
